Abstract:Precision cancer medicine is widely established, and numerous molecularly targeted drugs for various tumor entities are approved or in development. Personalized pharmacotherapy in oncology has so far been based primarily on tumor characteristics, e.g., somatic mutations. However, the response to drug treatment also depends on pharmacological processes summarized under the term ADME (absorption, distribution, metabolism, and excretion). Variations in ADME genes have been the subject of intensive research for more than five decades, considering individual patients' genetic makeup, referred to as pharmacogenomics (PGx). The combined impact of a patient's tumor and germline genome is only partially understood and often not adequately considered in cancer therapy. This may be attributed, in part, to the lack of methods for combined analysis of both data layers. Optimized personalized cancer therapies should, therefore, aim to integrate molecular information about the tumor and the germline, taking into account existing PGx guidelines for drug therapy. Moreover, such strategies should provide the opportunity to consider genetic variants of previously unknown functional significance. Bioinformatic analysis methods and corresponding algorithms for data interpretation need to be developed to consider PGx data in interdisciplinary molecular tumor boards, where cancer patients are discussed to provide evidence-based recommendations for clinical management based on individual tumor profiles. Significance Statement The era of personalized oncology has seen the emergence of drugs tailored to genetic variants associated with cancer biology. However, full potential of targeted therapy remains untapped due to the predominant focus on acquired tumor-specific alterations. Optimized cancer care must integrate tumor and patient genomes, guided by pharmacogenomic principles. An essential prerequisite for realizing truly personalized drug treatment of cancer patients is the development of bioinformatic tools for comprehensive analysis of all data layers generated in modern precision oncology programs.

How will the identification and therapeutic intervention of genetic targets in oncology evolve for future therapy?

Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review

State-of-the-Art Technologies to Interrogate Genetic/Genomic Components of Drug Response

Nongenetic evolution of the tumor: from challenges to new therapeutic opportunities

Personalized Medicine: Recent Progress in Cancer Therapy

With one eye on the future

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer Therapeutics

Advances in Personalized Oncology

Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes

Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes.

Discovery of novel therapeutic targets in cancer using patient-specific gene regulatory networks

Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling

Precision oncology: current and future platforms for treatment selection

Digital oncology, the dawn of a new era turning the clock back on tumor mass

The evolving landscape of tissue‐agnostic therapies in precision oncology

Precision Oncology: Evolving Clinical Trials across Tumor Types

The Next Big Questions in Cancer Research

Assessment of the Evolution of Cancer Treatment Therapies

Multi-OMICs and Genome Editing Perspectives on Liver Cancer Signaling Networks

Advances in Targeted Therapy for Cancer: Precision Medicine Approaches

Cytogenetics and Cytogenomics Evaluation in Cancer